Lymph node dissection: how much is enough?

Similar documents
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Invasive Bladder Transitional Cell Carcinoma OBJECTIVES

Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic

Ode to a node Lymph node dissec3on in prostate and bladder cancer

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity

346

When to Integrate Surgery for Metatstatic Urothelial Cancers

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

Radical Cystectomy Often Too Late? Yes, But...

Optimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University

EUROPEAN UROLOGY 60 (2011)

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density

BJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.

Conclusions. Keywords

Collection of Recorded Radiotherapy Seminars

Early radical cystectomy in NMIBC Marko Babjuk

Lymphadenectomy with Cystectomy: Is It Necessary

Panel: A Case-based Approach to the Management of Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

Open Radical Cystectomy Tips and Tricks in Males and Females

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Extent of Pelvic Lymph Node Dissection During Radical Cystectomy: Is Bigger Better?

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience

ROBOTIC VS OPEN RADICAL CYSTECTOMY

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer

Does skip metastasis or other lymph node parameters have additional effects on survival of patients undergoing radical cystectomy for bladder cancer?

Presentation with lymphadenopathy

Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer

Review Article Lymphadenectomy in Management of Invasive Bladder Cancer

Minimal Invasive Approach ro radical cystectomy: Results of the European multicentric study

Role of Pelvic Lymphadenectomy in the Treatment of Bladder Cancer: A Mini Review

Rochester Minnesota Mayo Clinic

Sang Eun Lee, Hakmin Lee, Hyun Hwan Sung, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han-Yong Choi, Byong Chang Jeong

The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC

Presentation with lymphadenopathy

The Role of Surgery in Metastatic Bladder Cancer. Maurizio Brausi Chairman ESOU Modena, ITALY

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life.

Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Bladder Cancer Guidelines

Does the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer Influence Disease-Free Survival? A Prospective Single-Center Study

The Role of Pelvic Lymph Node Dissection During Radical Cystectomy for Bladder Cancer

Neoadjuvant Treatment of. of Radiotherapy

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J.

Trimodality Therapy for Muscle Invasive Bladder Cancer

Debate: Whole pelvic RT for high risk prostate cancer??

Sentinel Lymph Node Biopsy in Other Tumours: Sentinel Lymph Node Biopsy in Other Tumours. Methodology. Results. Key Questions to Consider

A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing either open or robotic radical cystectomy

Highlighting Clinical Trials Muscle Invasive Bladder Cancer

Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer

2016 Uterine Cancer Annual Report

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Relevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:

including total number of retrieved and positive LNs in each area of dissection, operative duration and complications.

Linking Oncotype Dx results to SEER data and patient report to assess challenges in individualizing breast cancer care

SENTINEL LYMPH NODE CONCEPT IN OESOPHAGEAL CANCER

Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes

Cytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Soft Tissue Sarcoma. Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee

Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer

SLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA

Results of the ACOSOG Z0011 Trial

INVASIVE BLADDER CANCER

Lymphadenectomy in RCC: Yes, No, Clinical Trial?

Curie - davinci connection

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

A Quality Improvement Project: Decreasing the Time from Diagnosis to Surgery in Patients with Bladder Cancer

International Journal of Health Sciences and Research ISSN:

URETHRAL CANCER EPIDEMIOLOGY - 1

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact

The Feasibility of Robot-Assisted Laparoscopic Radical Cystectomy with Pelvic Lymphadenectomy: from the Viewpoint of Extended Pelvic Lymphadenectomy

Determining the Optimal Surgical Approach to Esophageal Cancer

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Partial Cystectomy for Invasive Bladder Cancer

Attachment #2 Overview of Follow-up

Neodjuvant chemotherapy

1. Introduction. Correspondence should be addressed to Franklin C. Lee; Received 5 August 2013; Accepted 24 October 2013

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

Surgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Nodal staging and lymphadenectomy in patients undergoing radical cystectomy

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience

The Extent of Lymphadenectomy at the Time of Radical Cystectomy for Bladder Cancer and its Impact on Prognosis and Survival

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Transcription:

1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive bladder cancer In last 20 years the focus has been on: Timing of surgery Type of urinary diversion Adjuvant or neoadjuvant chemotherapy Laparoscopic techniques But does the technique of surgery matter? YES Lymph node dissection Nodal drainage of the bladder Most experts agree that node dissection is an important component of cystectomy BUT How extensive a node dissection is enough?

2 Extent of Node Dissection Limited = obturator only Standard = to bifurcation of common iliac Extended = to IMA Mapping study using radioactive nanocolloid injected into detrusor Roth E URO 2010:57:205 Node mapping study (n=290, N+ = 81) % of positive nodes % of patients + nodes by level Node mapping study in 43 N+ patients Leissner J URol 2004:171:139 Vazino et al J Urol 2004 171:1830

3 USC Mapping study (n=408, 93 N+) Preop clinical stage < T2 Highest level of positive nodes III II I 28 % 15% 57 % Highest level of positive nodes III II I 21 % 17 % 62 % Impact of positive nodes: USC series (n=1054) Patients with nodes at Level I only have almost a 50% 5-year recurrence-free survival 1.00 RFS by most proximal extent of LN involvement (n=65) Probability of Survival 0.80 0.60 0.40 0.20 p=0.032 Level II + III Level I Stein J Urol 2003:170:35 0.00 0 1 2 3 4 5 6 7 8 Years Since Surgery

4 Chemotherapy is an important adjunct for Level III nodes Effect of adjuvant chemo on RFS in pts with positive LNs above the aortic bifurcation (n=30) Limited vs extended LND Consecutive series (1990-93 vs 1993-97) (n=184) All patients Organ-confined 1.00 p<0.001 Probability of Survival 0.80 0.60 0.40 0.20 No chemo (n=10) Chemo (n=20) 0.00 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 Years Since Surgery Poulson, Horn, Steven J Urol 1998:160:2015 Limited vs extended LND Two institutions 1987-2000, recurrence-free survival Cleveland Clinic Limited dissection 9n=336) Bern Extended dissection (n=322) SWOG 8710 Trial 317 patients 1987-98 randomized to MVAC + cystectomy vs cystectomy alone 109 institutions (half community hospitals) 106 different surgeons Type of node dissection none 24 (9%) limited 98 (37%) standard 146 (54%) Dhar J Urol 2008;179:873 Herr J et al. Urol 171:1823, 2004

5 SWOG 8710 Survival by number of nodes removed Impact of # nodes examined on overall survival after cystectomy SEER data 1988-1996 (n=1900) N0 < 10 N0 > 10 Herr J Urol 171:1823, 2004 Konety J Urol 2003:169:946 Probability of undergoing LND by year of cystectomy SEER data 1988-2004 (n=8000) Collaborative Group Extent of lymph node dissection 100 90 80 Any LND > 10 nodes > 10 nodes >5 nodes 70 60 50 40 30 20 10 None Limited Standard Extended 0 MSKCC n=553 Vanderbilt n=279 U Mich n=210 Baylor n=49 Hellenthal J Urol 2009:181:2490 Herr J Urol 171:1823, 2004

6 Node counts Influenced by pathologists diligence, node packaging, and patient differences Poor surrogate for the extent of dissection Konety, Herr, others recommend a minimum of 10 nodes for adequate node dissection Number of nodes required to detect first positive node Dangle J Urol 1010:183:499 Node Packaging May 2002-present Nodal tissue sent to pathology in individual packets Pic of packets No change in the basic limits of dissection

7 Extended Node Dissection No difference in N+ rate with node packaging Extended dissection Number of nodes removed Era # pts Median # nodes N+ (range) 100% No packaging 100% With packaging 80% 80% 1971-2001 1359 31 (1-96) 23 % 60% 40% 60% 40% 2002-2006 447 68 (0-132) 25 % 20% 0% < 15 15-30 > 30 20% 0% < 15 15-30 > 30 Updated from Stein JP et al J Urol 177:876, 2007 1971-2001 2005-2006 Extended dissection with packaging # nodes removed USC 2005-2006 (n=223) Number of positive nodes vs total nodes (n=54, 2005-2006) 120 60 50 40 30 20 10 100 80 60 40 20 20% cutoff 0 0-15 16-30 31-45 45-60 61-75 76-90 91-105 106-120 > 120 0 0 30 60 90 120 XY (Scatter) 1 XY (Scatter) 2 XY (Scatter) 3 XY (Scatter) 4

8 Complications of extended node dissection Time: extra 30-60 minutes Poulson, Brosner studies: no increase in complications USC experience: 2% lymphocele (no tx) and 2% lymphedema long term Lymph Node Dissection Conclusions Extent of node dissection has an impact on outcome A minimal or no node dissection is associated with worse outcome for both N+ and N- patients Patients with small volume nodal disease may be cured with a more extensive dissection Positive margins are deadly, and are associated with more limited node dissection. Lymph Node Dissection Questions? Is there additional benefit to the extended node dissection over the standard dissection in terms of regional or distant recurrence? Does our current N-stage system work in the face of extended dissection and node packaging? Does the 20% cutoff for node density still work?